Samsung Group may also set up another joint venture to make biosimilars this year, Kim said.

The Seoul-based group may exceed its target to generate 1.8 trillion won a year by 2020 from biopharmaceuticals because of the demand for those medicines, Executive Vice President Kim Tae Han said.